Skip to main content
SpringerLink
Log in

The Role of Prostate-Specific Antigen Velocity in the Diagnosis and Management of Prostate Cancer

  • Chapter
Prostate Biopsy

Part of the book series: Current Clinical Urology ((CCU))

  • 891 Accesses

Abstract

Interpretation of absolute PSA values can be confusing both when used for diagnosis and management. Clinicians are beginning to appreciate that PSA changes (kinetics) may provide important information beyond an absolute PSA value for assessing the risk of cancer presence, cancer significance, and risk of death from prostate cancer after curative intervention. Because PSAV correlates with the likelihood that life threatening disease is present, use of PSAV may help reduce the over diagnosis and over treatment of prostate cancer that has occurred with PSA screening. In addition, after curative intervention for prostate cancer, PSADT is a surrogate for survival and can be used to help identify those men with biochemical failure who are most likely to benefit from salvage treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005;14:590–595.

    Article  PubMed  Google Scholar 

  2. Carter HB, Pearson JD, Metter JE, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215–2220.

    Article  CAS  PubMed  Google Scholar 

  3. Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323–3328.

    CAS  PubMed  Google Scholar 

  4. Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: the effect of sampling interval and number of repeat measurements on prostate-specific antigen velocity. Urology 1995;45:591–596.

    Article  CAS  PubMed  Google Scholar 

  5. Riehmann M, Rhodes PR, Cook TD, et al. Analysis of variation in prostatespecific antigen values. Urology 1993;42:390–397.

    Article  CAS  PubMed  Google Scholar 

  6. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/mL range in male volunteers. J Urol 1996;155:1977–1980.

    Article  CAS  PubMed  Google Scholar 

  7. Eastham JA, Riedel E, Scardino PT, et al.; Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003:289:2695–2700.

    Article  CAS  PubMed  Google Scholar 

  8. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163–1167.

    CAS  PubMed  Google Scholar 

  9. Kadmon D, Weinberg AD, Williams RH, et al. Pitfalls in interpreting prostate specific antigen velocity. J Urol 1996;155:1655–1657.

    Article  CAS  PubMed  Google Scholar 

  10. Lujan M, Paez A, Sanchez E, et al. Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol 1999;162:1311–1313.

    Article  CAS  PubMed  Google Scholar 

  11. Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004;63:316–320.

    Article  PubMed  Google Scholar 

  12. Berger AP, Deibl M, Steiner H, et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 2005;64:240–245.

    Article  PubMed  Google Scholar 

  13. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860–864.

    Article  CAS  PubMed  Google Scholar 

  14. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174:877–881.

    Article  CAS  PubMed  Google Scholar 

  15. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. Urology 2002;59:889–893.

    Article  PubMed  Google Scholar 

  16. Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology 2004;63:309–313.

    Article  CAS  PubMed  Google Scholar 

  17. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125–135.

    Article  PubMed  Google Scholar 

  18. D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440–447.

    Article  PubMed  Google Scholar 

  19. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191–2196.

    Article  PubMed  Google Scholar 

  20. Carter HB, Ferrucci L, Metter EJ. PSA velocity and risk of prostate cancer death in the Baltimore Longitudinal Study of Aging. J Urol 2005;173:257. Abstract 951.

    Article  Google Scholar 

  21. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 2005;4:38–44.

    PubMed  Google Scholar 

  22. Pound CR, Partin AW, Eisenberger MA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–1597.

    Article  CAS  PubMed  Google Scholar 

  23. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872–18726.

    Article  PubMed  Google Scholar 

  24. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–1383.

    PubMed  Google Scholar 

  25. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancerspecific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–439.

    Article  CAS  PubMed  Google Scholar 

  26. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–1332.

    Article  CAS  PubMed  Google Scholar 

  27. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23:4975–4979.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James Buchanan Brady Urological Institute, John Hopkins School of Medicine, Baltimore, MD

    H. Ballentine Carter MD

Authors
  1. H. Ballentine Carter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Regional Urology, Cleveland Clinic Glickman Urological and Kidney Institute, USA

    J. Stephen Jones MD (Chairman, Associate Professor of Surgery (Urology) (Chairman, Associate Professor of Surgery (Urology)

  2. Cleveland Clinic Lerner College of Medicine at CWRU, Cleveland, OH, USA

    J. Stephen Jones MD (Chairman, Associate Professor of Surgery (Urology) (Chairman, Associate Professor of Surgery (Urology)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Carter, H.B. (2008). The Role of Prostate-Specific Antigen Velocity in the Diagnosis and Management of Prostate Cancer. In: Jones, J.S. (eds) Prostate Biopsy. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60327-078-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-078-6_6

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-790-7

  • Online ISBN: 978-1-60327-078-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation